Scopolamine to Treat Depression
Information source: National Institutes of Health Clinical Center (CC)
Information obtained from ClinicalTrials.gov on March 21, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Unipolar Depression; Bipolar Depression
Intervention: Scopolamine (Drug)
Phase: Phase 2
Sponsored by: National Institute of Mental Health (NIMH)
Patient Recruitment and Public Liaison Office, Phone: (800) 411-1222, Email: firstname.lastname@example.org
This study will examine the antidepressant effects of scopolamine in patients with major
depressive disorder or bipolar disorder. Scopolamine is commonly used to treat motion
sickness and diarrhea, and is sometimes given before anesthesia or during eye examinations.
In preliminary studies, scopolamine has shown strong antidepressant effects when given as an
intravenous (through a vein) infusion. This study will examine its effectiveness when given
through a skin patch and in pill form.
People between 18 and 50 years of age who have major depressive disorder or bipolar disorder
may be eligible for this study. Candidates are screened with a physical exam,
electrocardiogram (EKG), eye exam, blood and urine tests, psychiatric and clinical interviews
and neuropsychological testing.
Participants wear skin patches behind the ear and take pills according to a prescribed
regimen over an 8-week period. Half of the time the medications contain scopolamine and half
of the time they contain an "active" placebo called glycopyrrolate, a drug that produces side
effects similar to those that may be experienced with scopolamine, but that does not go into
Participants come to the NIH Clinical Center every 4 to 5 days while taking the medication
and then for two follow-up visits over the next 2 weeks for a physical exam and evaluations
with clinical rating scales. In addition, participants are asked to undergo two sessions of
cognitive testing and to have two positron emission tomography (PET) studies. Those who have
the PET scans also have a magnetic resonance imaging (MRI) scan. Participants can choose to
participate in the rest of the study without doing the PET scan.
PET is a diagnostic imaging tool that uses a radioactive chemical "tracer" to show cellular
activity in specific tissues of the body. For this procedure, a catheter (thin plastic tube)
is placed into an arm vein for injecting the tracer, and a second catheter is inserted into
an artery in the wrist to obtain arterial blood samples during the scan. The patient lies on
the scanner bed, wearing a special mask that is placed over the head to limit movement during
the scan. MRI uses a magnetic field and radio waves to produce pictures of the brain. For
this test, the subject lies on a table that is moved into the scanner (a metal cylinder),
wearing earplugs to muffle the noise of the machine during the scan.
Official title: The Antidepressant Efficacy of the Anticholinergic Scopolamine
Study design: Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Efficacy Study
Primary outcome: Change in Depression Severity
Despite the availability of a wide range of antidepressant drugs, clinical trials indicate
that 30% to 40% of patients with major depression fail to respond to first-line
antidepressant treatment, despite adequate dosage, duration, and compliance. Moreover, in
those patients who do experience symptomatic relief following conventional anti-depressant
treatment, clinical improvement is not evident for 3-4 weeks. Thus, there is a clear need to
develop novel and improved therapeutics for unipolar and bipolar depression.
The cholinergic system is one of the neurotransmitter systems implicated in the
pathophysiology of mood disorders. Evidence suggests that during major depressive episodes,
the cholinergic system is hypersensitive to acetylcholine. Agents that enhance muscarinic
cholinergic receptor function increase depressive symptoms in depressed subjects, and can
produce symptoms of depression in healthy individuals. The preclinical literature more
specifically implicates the muscarinic receptors and indicates that the use of muscarinic
antagonists, in the context of animal models of depression, results in improvement in the
behavioral analogs of depression.
Preliminary results obtained under protocol 03-M-0108 provide strong evidence for the
potential effectiveness of the anticholinergic scopolamine in rapidly producing clinically
significant antidepressant effects. We observed large reductions in Montgomery-Asberg
Depression Rating Scale (MADRS) scores that occurred over hours/days following i. v. infusion
of scopolamine, which stood in marked contrast to the 3-4 week period generally required for
conventional therapies. Moreover, these improvements were observed in subjects who had been
nonresponsive or incompletely responsive to conventional antidepressant therapies,
highlighting the potential for this treatment to benefit a larger percentage of individuals
with depression. The goal of this research project is to perform a clinical trial to
evaluate the efficacy of the muscarinic cholinergic receptor antagonist scopolamine
administered via transdermal patch on clinical symptoms of depression.
Minimum age: 18 Years.
Maximum age: 50 Years.
- INCLUSION CRITERIA:
Two groups of subjects will be recruited for studies under this protocol: unipolar
depressives and bipolar depressives. Subjects with unipolar or bipolar depression appear to
exhibit abnormal cholinergic function during the depressed phase, and no differences are
hypothesized to exist between MDD and BD depressives herein. However, while BD subjects
are more difficult to recruit, the evidence for cholinergic abnormalities has been
particularly compelling for BD. Moreover, observations from our pilot study suggest that
scopolamine will improve symptoms in both MDD and BD, a particularly persuasive observation
given BD notoriously has been difficult to treat. Thus, the magnitude of this serious
clinical problem justifies the inclusion of BD subjects. Therefore both groups will be
recruited. However, BD Type I subjects will be included only if they are currently stable
on lithium or valproate to reduce the risks associated with possible precipitation of
The presence of inclusion and exclusion criteria will be established using both an
unstructured clinical interview with a psychiatrist and the Structured Clinical Interview
for DSM-IV (SCID). Family history of mental illness will be obtained from the subject
using the Family Interview of Genetic Studies. We will recruit 24 subjects per group.
DEPRESSED SAMPLES: Subjects (ages 18-50) currently suffering from a major depressive
episode falling into one of the following subgroups:
1. . MAJOR DEPRESSIVE DISORDER (MDD): Subjects will be selected with primary MDD and
are currently depressed as defined by DSM-IV criteria for recurrent MDD and current
MADRS score in the moderately-to-severely depressed range (greater than or equal to
20). The duration of the index episode is greater than or equal to four weeks.
2. . BIPOLAR DISORDER TYPE II (BD): Subjects will be selected who meet DSM-IV criteria
for bipolar disorder Type I or II and are currently depressed, with MADRS score in the
moderately-to-severely depressed range (greater than or equal to 20). The duration of
the index episode is greater than or equal to four weeks.
Subjects will be recruited who are drug-naive or who have not received psychotropic drugs
for at least 3 weeks (8 weeks for fluoxetine) prior to screening. Subjects also will be
excluded if they have: a) serious suicidal ideation or behavior, or current delusions or
hallucinations, b) inability to provide informed consent, c) serious, unstable illnesses
including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including
ischemic heart disease, endocrinologic, neurologic, immunologic, or hematologic disease, d)
a history of drug or alcohol abuse within 6 months or alcohol or drug dependence in the
last five years (DSM IV criteria), e) not using a medically accepted means of contraception
and are a woman of childbearing potential, f) current pregnancy (documented by pregnancy
testing), g) current breast feeding, h) history of ulcerative colitis or toxic megacolon,
i) vision and/or hearing problems severe enough to interfere with testing, j)
electrocardiographic evidence of ischemia, arrhythmia, conduction defect, or myocardial
infarction, k) current blood pressure of greater than 160 mm Hg or less than 90 mm Hg
systolic, or greater than 90 mm Hg diastolic, l) clinically significant cerebrovascular or
cardiovascular disease, hypertension, congestive heart disease, angina pectoris, clinic
evidence of cerebrovascular disease, gross neurological impairment, hyperthyroidism, known
hypersensitivity or idiosyncracy to anticholinergic agents (e. g. skin rashes), glaucoma,
renal or hepatic impairment, m) current nicotine use or nicotine dependence within last
six months (due to the effects of nicotine on the cholinergic system) n) narrow angle
glaucoma (due to the possibility of exacerbation of this condition by scopolamine) o) age
greater than 50 years (to reduce the biological heterogeneity encompassed by the MDD and BD
criteria, since subjects with a late age-at onset for depression have a far greater
likelihood of having MRI correlates of cerebrovascular disease than age-matched, healthy
controls or age-matched, early-onset depressives), p) exposure within two weeks to
medications likely to affect mood or cognition or likely to interact with scopolamine (e. g.
narcotics or anti-cholinergic agents)- as verified by history and urine drug screen, q) HIV
positive status, r) history of gastric or intestinal obstructions, s) history of urinary
retention or bladder obstruction. During the course of this study, participants will be
unable to take some medications, including antidepressant or antianxiety agents, sleep
aids, diphenhydramine (e. g. Benedryl) or cough/cold preparations that contain
diphenhydramine or antihistamines. A detailed list of allowed and not allowed medications
is provided in Appendix B in the protocol.
We are not excluding comorbid anxiety disorders. Exclusion of patients with comorbid
anxiety disorders would affect the generalizability of our findings since a substantial
percentage of patients with major depression have these comorbid diagnoses. Instead, we
will exclude patients with this comorbid diagnosis only if it is believed to be of clinical
significance. Allowing participation by patients with histories of comorbid anxiety
disorders broadens the inclusion criteria to more closely approximate patients seen in real
Locations and Contacts
Patient Recruitment and Public Liaison Office, Phone: (800) 411-1222, Email: email@example.com
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States; Recruiting
NIH Clinical Center Detailed Web Page
Janowsky EC, Risch C, Janowsky DS. Effects of anesthesia on patients taking psychotropic drugs. J Clin Psychopharmacol. 1981 Jan;1(1):14-20. Review.
Starting date: August 2006
Last updated: March 8, 2008